Loading patent…
AssigneeAchillion Pharmaceuticals, Inc.
InventorsAvinash Phadke, Akihiro Hashimoto, Pingyun Chen, Senthil Kumar Kusalakumari Sukumar
Estimating the term…
The disclosure provides a crystalline sodium salt of ACH-0142684 comprising a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, a Form E polymorph, a Form F polymorph, a Form G polymorph, a Form H polymorph, a Form I polymorph, or a combination thereof, wherein the Form A, B, C, D, E, F, G, H, and I polymorph exhibits an X-ray powder diffraction pattern having peak locations in accordance with FIGS. 8; 12; 15; 21; 22; 27; 30, and 31, respectively.
The crystalline form of the sodium salt of ACH-1042684 comprising polymorph A.
The crystalline form of the sodium salt of ACH 1042684 comprising polymorph B.
The crystalline form of the sodium salt of ACH 1042684 comprising polymorph C.
15-27. (canceled)
The crystalline form of the sodium salt of ACH 1042684 comprising polymorph G.
32-39. (canceled)
A composition comprising a crystalline sodium salt of ACH-0142684, wherein at least 90% of the crystalline sodium salt of ACH-0142684 is the Form A polymorph, the Form B polymorph, the Form C polymorph, the Form D polymorph, the Form E polymorph, the Form F polymorph, the Form G polymorph, the Form H polymorph, the Form I polymorph, or a combination thereof.
42-45. (canceled)
Dependencies are inferred from the claim text.